spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  gabapentin 

 HSMN NewsFeed - 28 Aug 2024
Neuros Medical Receives FDA Approval for the Altius(R) Direct Electrical Nerve Stimulation System
Devices FDA
 HSMN NewsFeed - 15 Sep 2015
Depomed Files New Patent Infringement Lawsuit Against NUCYNTA(R) ER ANDA Filer
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 17 Aug 2015
European Commission Grants Marketing Authorisation for Unituxin(TM) (dinutuximab) for the Treatment of Paediatric High-Risk Neuroblastoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 13 Apr 2015
Depomed Announces Gralise(R) ANDA Litigation Settlement Confirming Exclusivity to 2024 and Dismissing Appeal
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 5 May 2014
Immune Pharmaceuticals Announces Phase 3 Development and Commercialization Strategy for AMIKET
Biopharmaceuticals
 HSMN NewsFeed - 29 Jan 2014
XenoPort Appoints Richard Kim, M.D., as Chief Medical Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 23 Jul 2013
XenoPort Announces Inclusion of Horizant (Gabapentin Enacarbil) in Guidelines for Long-Term Treatment of Restless Legs Syndrome/Willis-Ekbom Disease
Biopharmaceuticals Neurology
 HSMN NewsFeed - 27 Aug 2012
Depomed Licenses Acuform(R) Patents to Janssen Pharmaceuticals, Inc.
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 18 Jun 2012
XenoPort Appoints Ernest Mario, Ph.D., to Board of Directors
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 7 Jun 2012
GSK and XenoPort Receive FDA Approval for Horizant(R) for Postherpetic Neuralgia
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 May 2012
Acella Pharmaceuticals, LLC, Announces Approval of Generic Gabapentin Oral Solution
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 23 Jan 2012
EpiCept Corporation Receives Finalized FDA Guidance for AmiKet(TM) Phase III CIPN Program and Regulatory Strategy
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 Jan 2012
Astellas and XenoPort Announce Approval of Regnite(R) Tablets for Restless Legs Syndrome in Japan
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 4 Jun 2010
Mylan Receives Approval for Generic Version of Neurontin(R) Tablets
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 5 Mar 2010
XenoPort Restructures to Focus on Key Programs
Biopharmaceuticals
 HSMN NewsFeed - 27 Jan 2010
EpiCept Receives Orphan Drug Designation for EpiCept NP-1 in U.S.
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Apr 2009
XenoPort Announces Election of Co-Promotion Option for Solzira
Biopharmaceuticals
 HSMN NewsFeed - 9 Jan 2009
GSK and XenoPort Resubmit New Drug Application for Solzira(TM) in Restless Legs Syndrome
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 16 Sep 2008
GSK and XenoPort Announce Submission of New Drug Application Requesting FDA Approval of Solzira(TM) for Restless Legs Syndrome
Biopharmaceuticals
 HSMN NewsFeed - 23 Jul 2008
Depomed's ProQuin(R) XR Achieves First Marketing Authorization in Europe
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 22 Jul 2008
Santarus and Depomed Announce U.S. Promotion Agreement for GLUMETZA Prescription Products
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 24 Mar 2008
Depomed Doses First Patient in New Phase 3 Clinical Trial of Gabapentin GR in Postherpetic Neuralgia
Biopharmaceuticals
 HSMN NewsFeed - 28 Feb 2008
XenoPort and GlaxoSmithKline Report Positive Top-Line Results of Final Pivotal Trial of XP13512/GSK1838262 for Restless Legs Syndrome
Biopharmaceuticals
 HSMN NewsFeed - 20 Feb 2008
Depomed Names Abid Rawn Vice President of Sales and Marketing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Feb 2008
EpiCept Announces Encouraging Results of Phase II Trial for NP-1 Cream in Diabetic Peripheral Neuropathy
Biopharmaceuticals
 HSMN NewsFeed - 6 Feb 2008
Apex Bioventures and Dynogen Pharmaceuticals Announce Definitive Merger Agreement
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 2 Jan 2008
Depomed Receives FDA Approval for 1000 mg Strength Tablets of Glumetza
Biopharmaceuticals FDA Endocrinology Drug Delivery
 HSMN NewsFeed - 3 Dec 2007
Depomed Names Michael Sweeney Vice President of Product Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Oct 2007
Depomed and King Pharmaceuticals Terminate Promotion Agreement for GLUMETZA(TM)
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 11 Oct 2007
Depomed Announces Retirement of Chief Financial Officer John F. Hamilton
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Sep 2007
Depomed and Watson Expand ProQuin(R) XR Promotion Agreement to Include Ob/Gyn Field
Biopharmaceuticals
 HSMN NewsFeed - 21 Sep 2007
Court Rules for Pfizer in Patent Infringement Case on Neurontin
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 17 Sep 2007
Depomed Announces Reduction in Force
Biopharmaceuticals
 HSMN NewsFeed - 27 Aug 2007
Dr. John Fara Retires as Chairman, President and CEO of Depomed; Mr. Carl Pelzel Appointed President and CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Jul 2007
EpiCept Announces Phase III Study of EpiCept(TM) NP-1 for the Treatment of Chemotherapy Induced Peripheral Neuropathy
Biopharmaceuticals
 HSMN NewsFeed - 10 Jul 2007
Depomed Announces Results of Phase 3 Clinical Trial for Gabapentin GR(TM) In Postherpetic Neuralgia
Biopharmaceuticals
 HSMN NewsFeed - 5 Jul 2007
Depomed Reacquires the Rights to ProQuin(R) XR
Biopharmaceuticals Acquisitions Licensing
 HSMN NewsFeed - 25 Apr 2007
XenoPort Reports Positive Top-Line Phase 3 Trial Results of XP13512 in Restless Legs Syndrome
Biopharmaceuticals
 HSMN NewsFeed - 10 Apr 2007
EpiCept Initiates Two Phase IIb Trials with NP-1
Biopharmaceuticals
 HSMN NewsFeed - 2 Apr 2007
Depomed Files Prior Approval Supplement for 1000 mg Strength Tablets of Glumetza
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 12 Mar 2007
Depomed Files Investigational New Drug Application for Gabapentin GR for the Treatment of Postmenopausal Hot Flashes
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 12 Feb 2007
Depomed and Biovail Sign License Agreement for AcuForm(TM) Drug Delivery Technology
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 8 Feb 2007
GlaxoSmithKline and XenoPort Announce Agreement on Late-Stage Compound for RLS and Neuropathic Pain
Biopharmaceuticals
 HSMN NewsFeed - 19 Jan 2007
Pharmos Announces Clinical Data from Phase 2a Trial of Cannabinor for Capsaicin-induced Pain
Biopharmaceuticals
 HSMN NewsFeed - 21 Dec 2006
Depomed Receives $10 Million License Fee from Esprit and Withdraws Arbitration Proceeding
Biopharmaceuticals Licensing Litigation
 HSMN NewsFeed - 20 Dec 2006
Depomed Announces Sweeping Interim Victory in Litigation against Ivax
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 18 Dec 2006
Depomed Delivers Notice of Breach and Demand for Arbitration to Esprit Pharma
Biopharmaceuticals Drug Delivery Litigation
 HSMN NewsFeed - 19 Oct 2006
PharmaNova Grants Exclusive U.S. License to Depomed for Extended Release Gabapentin Use in Hot Flashes
Biopharmaceuticals Licensing
 HSMN NewsFeed - 18 Oct 2006
Depomed Obtains Exclusive License to Gabapentin Use in Hot Flashes
Biopharmaceuticals Licensing
 HSMN NewsFeed - 6 Jul 2006
Depomed Names Matthew Gosling Vice President, Legal and General Counsel
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Jun 2006
King Pharmaceuticals and Depomed Announce Agreement to Co-Promote Glumetza(TM)
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 10 May 2006
Depomed Finalizes Phase III Clinical Trial Protocol for Gabapentin GR(TM)
Biopharmaceuticals Drug Delivery
Return to NewsFeed  

 Additional items found! 73

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 73 additional stories matching:
gabapentin
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.